PFE: Pfizer

_Created 2026-11-03 09:00 ET. Screening/research, not investment advice._

Business

Large-cap pharma (Eliquis, Prevnar, Vyndaqel, Padcev, COVID products declining). TRAI sector: Healthcare. Top 60d ρ in candidates: REGN 0.60 (TRAI /api/correlations).

2026-11-03 09:00 update

• Q3 (BMO): rev $16.58B vs $15.87B, adj EPS $0.87 vs $0.73; FY26 rev $62–64B (from $60.5–62.5B), adj EPS $2.95–3.05 (from $2.80–3.00) (Business Wire). FY EPS consensus was $2.96 (Reuters), so the raise roughly meets it. Pre-market −0.9% after +1.6% unexplained AH Monday.
• Report

2026-11-06 15:00 update — cluster-5 soft after Thu crush

• Thu −2.96%; Fri ~15:09 ~29.365 / ~−1.72% (still soft vs XLV flat). SM Healthcare ×5 residual (suspended). Cluster 5 (avg ρ 0.633); PFE–GILD 0.76, PFE–LLY 0.66; MRNA–PFE only 0.45 — not automatic MRNA read-through (S-149).
• Thu crush driver: unknown / secondary profit-taking (MarketBeat 11-05) [S]; no new Thu earnings reprint.
• Source: 2026-11-06 15:00 healthcare split.